Annamycin

Star0

DB06420InvestigationalSmall molecule

Investigated for use/treatment in breast cancer and leukemia (unspecified).

Mechanism: Annamycin belongs to the anthracycline class of drugs, and has a pleiotropic mechanism of action where it targets topoisomerase II, causing strand breaks in DNA. Annamycin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.
Curator reviewed
Primary indication: Investigated for use/treatment in breast cancer and leukemia (unspecified).Curator reviewed
Formula / weight: C₂₆H₂₅IO₁₁ · 640.379 g/mol (avg)
Code names: AR-522

Resolves to

Compound

UNIISNU299M83QCAS92689-49-1

Structure

InChIKeyCIDNKDMVSINJCG-GKXONYSUSA-NSMILESC[C@@H]1O[C@@H](O[C@H]2C[C@@](O)(CC3=C2C(O)=C2C(=O)C4=CC=CC=C4C(=O)C2=C3O)C(=O)CO)[C@H](I)[C@H](O)[C@H]1O

Targets

P11388TOP2A

Transporters

P08183ABCB1

What you can answer from here — as of April 23, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1TransporterSubstrate / inhibitor direction, not just membership

Listed above

41Drug interactionsStructured to mechanism, not free text

7Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Annamycin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account